Review





Similar Products

components  (MedChemExpress)
96
MedChemExpress components
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Components, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/components/product/MedChemExpress
Average 96 stars, based on 1 article reviews
components - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
dlin mc3 dma  (Alnylam Inc)
86
Alnylam Inc dlin mc3 dma
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Dlin Mc3 Dma, supplied by Alnylam Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dlin mc3 dma/product/Alnylam Inc
Average 86 stars, based on 1 article reviews
dlin mc3 dma - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
dlin dma mc3  (MedChemExpress)
93
MedChemExpress dlin dma mc3
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Dlin Dma Mc3, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dlin dma mc3/product/MedChemExpress
Average 93 stars, based on 1 article reviews
dlin dma mc3 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
benchmark d lin mc3 dma lipid  (MedChemExpress)
96
MedChemExpress benchmark d lin mc3 dma lipid
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Benchmark D Lin Mc3 Dma Lipid, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/benchmark d lin mc3 dma lipid/product/MedChemExpress
Average 96 stars, based on 1 article reviews
benchmark d lin mc3 dma lipid - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
dlinmc3 dma  (MedChemExpress)
96
MedChemExpress dlinmc3 dma
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Dlinmc3 Dma, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dlinmc3 dma/product/MedChemExpress
Average 96 stars, based on 1 article reviews
dlinmc3 dma - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
dma7100  (Hitachi Ltd)
99
Hitachi Ltd dma7100
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Dma7100, supplied by Hitachi Ltd, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dma7100/product/Hitachi Ltd
Average 99 stars, based on 1 article reviews
dma7100 - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier
p re ss  (MedChemExpress)
96
MedChemExpress p re ss
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
P Re Ss, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p re ss/product/MedChemExpress
Average 96 stars, based on 1 article reviews
p re ss - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
dlin mc3 dma  (MedChemExpress)
96
MedChemExpress dlin mc3 dma
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Dlin Mc3 Dma, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dlin mc3 dma/product/MedChemExpress
Average 96 stars, based on 1 article reviews
dlin mc3 dma - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
viscoelasticity measuring apparatus  (Hitachi Ltd)
99
Hitachi Ltd viscoelasticity measuring apparatus
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Viscoelasticity Measuring Apparatus, supplied by Hitachi Ltd, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/viscoelasticity measuring apparatus/product/Hitachi Ltd
Average 99 stars, based on 1 article reviews
viscoelasticity measuring apparatus - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier

Image Search Results


A) Chemical structures of lipid components used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.

Journal: bioRxiv

Article Title: Systemic delivery of CRISPR-Cas9 nickase suppresses oncogene amplified cancer progression

doi: 10.64898/2026.04.26.720919

Figure Lengend Snippet: A) Chemical structures of lipid components used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.

Article Snippet: The following components were purchased from MedChemExpress; DLin-MC3-DMA (HY-112251), DOTAP (HY-112754A), 306-O12B (HY-W590532), DMG-PEG 2000 (HY-112764), DOPC (HY-113424A), and DSPE-PEG-Maleimide (HY-140740).

Techniques: In Vivo, Ex Vivo, Control, Imaging